CEBPB and familial dilated cardiomyopathy: C/EBPβ up‐regulated Ang(1–7), which decreased ACE, AT1R and AT2R levels, and up‐regulated MasR expression levels 7, 23, which ultimately prevented DCM progression, whereas valsartan increased Ang(1–7) levels much lower than C/EBPβ.